Vertex has recorded some 25,000 prescriptions for Journavx since its January approval and is in the process of getting big ...

The biotech’s Huntingtin-targeting molecule lowered blood levels of the protein and elicited functional improvements in ...

Beam Therapeutics and Verve Therapeutics have each built their lead candidates on a technique billed as a safer alternative ...

Bristol Myers Squibb has made significant cuts to its workforce since last year as part of a strategic reorganization aimed ...

BNT327, a PD-L1/VEGF therapy, is still currently being manufactured in China, but BioNTech is working to establish a ...

On the FDA’s docket this month are two expansion bids, one for GSK’s asthma drug Nucala into COPD and another for Merck’s ...

The cell and gene therapy space in recent months has hit several speedbumps, including layoffs, dropped drugs and ...

The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...

The FDA’s user free programs account for just under half of the agency’s budget—money that could be imperiled by the recent ...

As the Trump administration—including HHS Secretary Robert F. Kennedy Jr.—plays fast and loose with scientific studies and ...

The American Association for Cancer Research’s annual conference featured updates from several companies on key candidates ...

Following challenges with its drug candidate bexotegrast and announcement of a limited-duration stockholder rights program, ...